Evaluation of the efficacy of palonosetron for prevention of chemotherapy-induced nausea and vomiting in patients with gastric cancer treated with S-1 plus cisplatin

Katsunobu Oyama1 · Sachio Fushida1 · Masahide Kaji2 · Toshiya Takeda3 · Kazuhisa Yabushita4 · Hideaki Nezuka5 · Shinichi Kinami6 · Naotaka Kadoya7 · Yuki Takai8 · Yuji Tsukioka9 · Shigekazu Ohyama10 · Kunihiro Tsuji11 · Tomoya Tsukada1 · Jun Kinoshita1 · Takashi Fujimura1 · Tetsuo Ohta1

Received: 19 August 2015 / Accepted: 13 October 2015 / Published online: 27 October 2015 © The Author(s) 2015. This article is published with open access at Springerlink.com

Abstract

Purpose The purpose of our study was to evaluate the efficacy of a new combination antiemetic therapy consisting of palonosetron, aprepitant, and dexamethasone in gastric cancer patients undergoing chemotherapy with S-1 plus cisplatin.

Methods This prospective, multi-institutional observational study assessed patient-reported nausea, vomiting, use of rescue therapy, change of dietary intake, and Functional Living Index-Emesis (FLIE) questionnaire results. The percentages of patients showing complete response (CR; no emesis and non-use of any rescue antiemetics) and complete protection (CP; no significant nausea and non-use of any rescue antiemetics), change of dietary intake, and impact of chemotherapy-induced nausea and vomiting on daily life during the overall (0–120 h after cisplatin administration), acute (0–24 h), and delayed (24–120 h) phases were examined. These findings were compared with our previous study, which used granisetron, aprepitant, and dexamethasone, to assess the relative effectiveness of palonosetron versus granisetron in combination antiemetic therapy.

Results Of the 72 included patients, 66 (91.6 %), 70 (97.2 %), and 50 (69.1 %) achieved CR, and 48 (66.7 %), 61 (84.7 %) and 49 (68.1 %) achieved CP during the overall, acute, and delayed phases of cisplatin administration, respectively. Approximately half of the patients had some degree of anorexia. FLIE results indicated that 78.6 % of patients maintained their quality of life. Palonosetron was not superior to granisetron in combination antiemetic therapy.

Conclusions Three-drug combination antiemetic therapy with palonosetron, aprepitant, and dexamethasone was tolerable in gastric cancer patients undergoing treatment with S-1 plus cisplatin. The predominance of palonosetron to granisetron was not demonstrated in this study.
Keywords Palonosetron · Gastric cancer · CINV · Anorexia · QOL

Introduction

Chemotherapy-induced nausea and vomiting (CINV) is a common adverse event observed in patients with cancer who receive chemotherapy [1] and is one of the greatest fears of patients receiving chemotherapy [2, 3]. Inadequate control of CINV can lead to dehydration, nutritional deficiencies, and electrolyte imbalances, which may impair functional and mental activities and quality of life (QOL), increase the use of healthcare resources, and occasionally cause treatment delay or discontinuation [4–6]. Generally, CINV persists for approximately 5 days after administration of emetogenic antitumor agents. CINV occurring within the first 24 h has been defined as acute and that occurring after >24 h as delayed [7].

Corticosteroids have long been used as antiemetic agents to treat CINV [8], being effective for both acute and delayed emesis. The introduction of selective serotonin [5-hydroxytryptamine-3 (5-HT₃)] receptor antagonists (RAs), such as ondansetron, dolasetron, and granisetron revolutionized the control of CINV. 5-HT₃Rs are used to treat patients receiving moderate to highly emetogenic chemotherapy, with protective effects mainly in acute emesis. Although combinations of corticosteroids and 5-HT₃RA have been standard for the management of CINV, >50 % of patients continue to vomit in response to highly emetogenic chemotherapy, such as high-dose cisplatin [9], suggesting that this combination antiemetic therapy prevents vomiting in the acute phase, but not in the delayed phase [10–12]. Delayed nausea also tends to be more severe and less responsive to antiemetic therapy than acute nausea.

Gastric cancer is one of the major causes of cancer deaths worldwide, and chemotherapy is the main treatment option for patients with advanced stage disease. A standard chemotherapeutic regimen for advanced gastric cancer consists of a combination of cisplatin plus fluoropyrimidine, which induces CINV. A large phase III trial of S-1, an orally administered 5-fluorouracil analog, plus cisplatin in patients with advanced gastric cancer who received combinations of corticosteroids and 5-HT₃RAs for management of CINV found that emesis occurred in 36 % of these patients and nausea in 67 % [13].

Recently, two novel anti-CINV agents have become available, the neurokinin-1 (NK₁) RA aprepitant and the new generation 5-HT₃RA palonosetron, both of which were found to prevent delayed-phase CINV. An observational study testing the combination of aprepitant, granisetron and dexamethasone in patients receiving chemotherapy with S-1 plus cisplatin for gastric cancer found that complete response (CR; no emesis and non-use of any rescue antiemetics) rates overall and during the acute and delayed phases of chemotherapy administration were 88.7, 98.1, and 88.7 %, respectively, and complete protection (CP; no significant nausea and non-use of any rescue antiemetics) rates during the three phases of chemotherapy were 67.9, 96.2, and 67.9 %, respectively [14]. Similarly, a study of triplet antiemetic treatment with a corticosteroid, a first generation 5-HT₃RA and NK₁RA reported that this largely alleviated acute and some delayed emesis, but found that delayed nausea rates were unacceptably high [15].

Palonosetron is a new generation 5-HT₃RA, differing from first generation 5-HT₃RAs in its pharmacokinetic and pharmacodynamic profiles, and may be uniquely suited to treat both early and delayed CINV. Four phase III clinical trials found that CINV prevention rates were higher with palonosetron than with first-generation 5-HT₃RAs [16–19]. Palonosetron has a longer elimination half-life (t½) and a greater receptor-binding affinity than first-generation 5-HT₃RAs [20]. Moreover, it has been shown to trigger 5-HT₃ receptor internalization and prolong inhibition of receptor function [21]. Moreover, mechanistic studies using palonosetron and an NK₁RA suggest interactions between the 5-HT₃ receptor and NK₁ receptor neurotransmitter pathways [22].

When compared with other 5-HT₃RAs, palonosetron was found to significantly reduce subjective sensations of nausea [23]. A pooled analysis of phase III clinical trials comparing palonosetron with first-generation 5-HT₃RAs found that palonosetron was superior in controlling nausea [24] and may therefore be superior in controlling delayed nausea.

This prospective observational study assessed the antiemetic efficacy and tolerability of palonosetron, combined with dexamethasone and aprepitant, in patients with advanced gastric cancer receiving S-1 plus cisplatin chemotherapy. By performing this study in patients similar to those who received triplet antiemetic therapy with granisetron, dexamethasone and aprepitant [14], we were able to compare the relative effectiveness of palonosetron and granisetron in combination antiemetic therapy for patients with gastric cancer.

Methods

Design

This was a multi-institutional, prospective, observational, non-comparative study involving 20 institutions of the Digestive Disease Support Organization (DDSO). All patients provided written informed consent, and
the study protocol was approved by the institutional review board at each participating center. Moreover, the study was performed in accordance with the principles of the Declaration of Helsinki (Clinical trial ID: UMIN000009016).

**Eligibility criteria**

The study involved high or moderately emetogenic, chemotherapy-naive patients scheduled to receive their first course of chemotherapy with S-1 (80 mg/m²) and cisplatin (60 mg/m²) for pathologically confirmed gastric cancer. All patients were aged ≥20 years and had an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0–2. Patients with any vomiting, retching, or nausea [National Cancer Institute (NCI) ≥ grade I] in the 24 h before the start of chemotherapy and those using any drug with potential antiemetic efficacy 48 h before chemotherapy were excluded. In addition, patients receiving radiation therapy to the abdomen or pelvis less than 1 week before treatment, those with a symptomatic primary or metastatic central nervous system malignancy, those at risk of vomiting for other reasons (e.g., epilepsy, active peptic ulcer, and gastrointestinal obstruction), and those with any uncontrolled disease other than malignancy that may pose an unwarranted risk, as determined by the investigator, were also excluded.

**Chemotherapy**

All patients received S-1 plus cisplatin therapy as described in the SPIRITS trial [13], the standard chemotherapy regimen for advanced gastric cancer in Japan. S-1 (80 mg/m²) was administered orally twice daily for the first 3 weeks of each 5-week cycle. Cisplatin was administered as an intravenous infusion of 60 mg/m² on day 8 of each cycle.

**Antiemetic treatment**

Patients received the combination of antiemetics recommended in the 2010 Japanese Society of Clinical Oncology (JSCO) Guidelines for Antiemetics in Oncology [25]. On day 1, all patients received oral aprepitant 125 mg 60 min before cisplatin infusion plus intravenous dexamethasone 9.9 mg and intravenous palonosetron 0.75 mg 30 min before cisplatin infusion. On days 2 and 3, patients received oral aprepitant 80 mg once daily each morning and oral dexamethasone 8 mg bid, and on day 4 patients received oral dexamethasone 8 mg bid. Patients were also prescribed a rescue antiemetic, to be used only when nausea and vomiting developed during the 120-h observation period.

**Response definitions**

The primary endpoint was the proportion of patients achieving CR during the overall study phase. No vomiting was defined as no vomiting, retching, or dry heaves. Secondary endpoints included the rate of CP. No significant nausea was defined as nausea scores of 0 and 1, and as nausea that does not interfere with normal patient activities; changes in dietary intake; absence of vomiting and no nausea; and the impact of CINV on daily life, as measured by the FLIE, during the overall, acute, and delayed phases. Safety was evaluated based on physical examinations, including vital signs, routine clinical laboratory tests, and adverse event reporting. Toxicity grades were assessed using the NCI Common Terminology Criteria for Adverse Events (NCI-CTCAE) v4.0. (http://ctep.cancer.gov/forms/CTCAEv4.pdf). Any adverse events were determined by the investigator to be possibly, probably, or definitively related to the study drug.

**Statistical analysis**

In our previous study, CR was observed in 88.7 % and CP in 67.9 % of patients. To realize an equivalent
antiemetic effect with palonosetron, the expected CR rate was set at 89%, the threshold CR rate at 77% and the expected CP rate at 80%. Using these parameters, we calculated that an estimated sample size of 63 subjects was required to provide a power of 80%, assuming a normal equation method and an overall significance level of 0.05. Assuming that approximately 15% of subjects would be withdrawn or drop out, the target sample size was set at 75 subjects. Rates of CR and CP, food intake and impact on daily life in this study were compared with those in our previous [14] using chi-squared tests. All statistical analyses were performed using the Statistical Package for Social Sciences (SPSS) software version 11.0.

Results

Patient characteristics

Between November 2012 and May 2014, 75 patients were enrolled at 14 centers in Japan. Of these, 72 satisfied the eligibility criteria; the three patients who were excluded did not receive cisplatin injections. The baseline demographic and clinical characteristics of the patients are described in Table 1. Of the 72 patients, 58 (80.6%) were male, and the median age of the patients was 65 years.

Antiemetic outcomes

Antiemetic outcomes are shown in Fig. 1 and Table 2. CR during the overall, acute, and delayed phases of cisplatin administration was achieved by 66 (91.6%), 70 (97.2%) and 66 (91.6%) patients, respectively, and CP during these phases was achieved by 48 (66.7%), 61 (84.7%), and 49 patients (68.1%), respectively.

Assessment of the QOL

Of the 72 eligible patients, 70 completed the FLIE questionnaires (Table 3). Over the 5 day study period, 55 patients (78.6%) had total FLIE scores of >108, with 54 (77.1%) having a nausea domain score of >54 and 64 (91.4%) having a vomiting domain score of >54, indicating that CINV had minimal or no impact on daily life. During the acute phase, 62 patients (88.6%) had total FLIE scores, 63 (90.0%) had nausea domain scores and 68 (97.2%) had vomiting domain scores indicating that CINV had minimal or no impact on daily life. During the delayed phase, 55 patients (78.6%) had total FLIE scores, 54 (77.1%) had nausea domain scores and 66 (94.3%) had vomiting domain scores indicating that CINV had minimal or no impact on daily life.
Table 3  QOL assessment based on FLIE questionnaire

| FLIE item                              | Overall (0–120 h) | Acute (0–24 h) | Delayed (24–120 h) |
|----------------------------------------|-------------------|----------------|-------------------|
|                                        | No. of patients  | %              | No. of patients  | %              | No. of patients  | %              |
|                                        | Total            | NIDL           | Total            | NIDL           | Total            | NIDL           |
| FLIE total score                       | 70               | 55             | 70               | 62             | 70               | 55             | 78.6
| Nausea domain total score             | 70               | 54             | 70               | 63             | 70               | 54             | 77.1
| Vomiting domain total score           | 70               | 64             | 70               | 68             | 70               | 66             | 94.3

NIDL no or minimal impact on daily life, defined as domain FLIE score of >54 and total FLIE score of >108

Dietary intake

Approximately half of the patients had some degree of anorexia, with the decrease in oral intake being more predominant during the delayed phase (Fig. 2). The volume of dietary intake was reduced by half in 30 % of patients. Additionally, 5 % of these patients could not consume any food or beverage during the delayed phase.

Comparison between these results and those of our previous study

A comparison of CR, CP, diet intake and impact on daily life in this study and that of our previous study evaluating the combination of aprepitant, granisetron and dexamethasone as an antiemetic in advanced cancer patients treated with cisplatin and S-1 showed no significant differences in any of these parameters (Table 4).

Table 4  Comparison of efficacy outcomes with those of a previous study assessing the combination of granisetron, aprepitant, and dexamethasone

|                                      | Present study (palonosetron/aprepitant/granisetron) (%) | Previous studya (granisetron/aprepitant/granisetron) (%) |
|--------------------------------------|--------------------------------------------------------|--------------------------------------------------------|
| Complete response                    |                                                        |                                                        |
| Acute                                | 97.2                                                   | 98.1                                                   |
| Delayed                              | 91.6                                                   | 88.7                                                   |
| Overall                              | 91.6                                                   | 88.7                                                   |
| Complete protection                  |                                                        |                                                        |
| Acute                                | 84.7                                                   | 96.2                                                   |
| Delayed                              | 68.1                                                   | 67.9                                                   |
| Overall                              | 66.7                                                   | 67.9                                                   |
| Reduction of diet intake             |                                                        |                                                        |
| Acute                                | 20.9                                                   | 18.8                                                   |
| Delayed                              | 55.6                                                   | 54.0                                                   |
| Overall                              | 55.6                                                   | 54.0                                                   |
| Impact on daily life (FLIE)          |                                                        |                                                        |
| Acute                                | 88.6                                                   | 98.0                                                   |
| Delayed                              | 78.6                                                   | 79.5                                                   |
| Overall                              | 78.6                                                   | 79.5                                                   |

a From Ref. [14]

Safety

Overall, antiemetic therapy was well tolerated. Adverse events considered by the investigator to be possibly, probably, or definitely related to the study drug included anorexia in nine (12.5 %) patients, diarrhea in six (8.3 %), and hiccups and constipation in one (1.4 %) each. No serious adverse events appeared related to the study drug.

Discussion

Palonosetron, a new 5-HT3RA, first became available in 2003, the same year as aprepitant. Standard antiemetic therapy with corticosteroid and a first-generation 5-HT3RA
provided significant advances in controlling acute emesis, but provided minimal benefit against delayed emesis. Palonosetron has a stronger binding affinity to its receptor and a longer plasma-elimination half-time than first-generation 5-HT₃RAs. As CINV can persist for several days, a longer acting 5-HT₃RA may be valuable in its treatment. Clinical trials have shown that palonosetron was effective in preventing both acute and delayed CINV [15–18]. Two phase III randomized trials in patients receiving moderately emetogenic chemotherapy showed that monotherapy with palonosetron better prevented delayed phase emesis than ondansetron [15] or dolasetron [16]. Moreover, palonosetron was found to be superior to ondansetron in patient receiving highly emetogenic chemotherapy [17]. The most noteworthy differences between palonosetron and first-generation 5-HT₃RAs occurred during the delayed phase. Although the latter two trials allowed dexamethasone pre-treatment at the investigator’s discretion, only one of these trials [17] found that concomitant dexamethasone was associated with antiemetic effects. A phase III trial comparing the anti-CINV effects of palonosetron plus dexamethasone versus granisetron plus dexamethasone in patients receiving highly emetogenic chemotherapy found that palonosetron was non-inferior to granisetron during the acute phase and superior to granisetron during the delayed phase [18]. A pooled-analysis of phase III trials comparing palonosetron with first-generation 5-HT₃RAs in combination with corticosteroid showed that palonosetron was associated with higher rates of CR, CP, and absence of emesis and nausea [28]. Nevertheless, another meta-analysis found that the superiority of palonosetron was unclear in trials in which patients were administered dexamethasone [29]. At present, therefore, the superiority of palonosetron when combined with corticosteroid remains unclear.

Triplet antiemetic therapy, involving a 5-HT₃RA, a corticosteroid and an NK₁RA, is now standard for patients receiving highly emetogenic chemotherapy. It is unclear, however, whether palonosetron is more effective against delayed emesis when administered with an NK₁RA. Several single-arm studies found that palonosetron had additional antiemetic efficacy when added to aprepitant and dexamethasone in patients with gynecological, head/neck and lung cancer [29–31]. Only one phase III trial, the TRIPLE study, compared granisetron and palonosetron added to basal antiemetic therapy with NK₁RA and corticosteroid, finding that palonosetron was superior to granisetron in preventing delayed emesis and nausea [32]. It also remains unclear whether palonosetron and NK₁RA act synergistically. In a recent report with gynecological cancer patients treated with moderately emetogenic chemotherapy including paclitaxel and carboplatin, the antiemetic effect of triplet therapy with palonosetron plus aprepitant plus dexamethasone was equivalent with triplet therapy with granisetron plus aprepitant plus dexamethasone [33]. The trial described here found that triple combination antiemetic therapy with palonosetron, aprepitant and dexamethasone for delayed emesis was well tolerated, but that the addition of palonosetron to aprepitant and dexamethasone was no more effective than the addition of granisetron to aprepitant and dexamethasone. However, the prolonged antiemetic effect of palonosetron may have been masked when administered with other antiemetic agents, including an NK₁RA.

The discrepancy between our results and those of the TRIPLE trial may be due to the efficacy of previous triplet therapy with granisetron, dexamethasone and aprepitant being sufficient for gastric cancer patients treated with S-1 plus cisplatin, masking any additional effects of palonosetron. In fact, the CINV control rates in our studies were superior to those of other studies in patients with different types of cancer receiving several chemotherapeutic regimens.

Medical economics is an important issue in clinical practice and must be balanced with the results of evidence-based medicine. The drug costs of antiemetics including palonosetron was JPY 27,653 and JPY 16,808 with granisetron per course of chemotherapy. In the present study, the drug replacement from granisetron to palonosetron is not worth the cost.

This study had several limitations. First, the study cohort was limited to patients with gastric cancer receiving an initial course of S-1 plus cisplatin chemotherapy. Patients with other types of cancer receiving other chemotherapeutic regimens may differ in response to triple antiemetic regimens that include palonosetron. Second, the number of enrolled patients was relatively small, and the percentages of female (14/72) and younger (median age 65 years old) patients were low. This is important as female sex and younger age are risk factors for emesis. Third, our study was an observational study, such that patients and caregivers were not blinded to the therapeutic regimens. Randomized controlled trials with a greater number of subjects are required to verify the findings presented here.

In conclusion, the tolerability of triple combination antiemetic therapy with palonosetron, aprepitant and dexamethasone was satisfactory. Nevertheless, we did not observe an additional effect of palonosetron in patients with gastric cancer treated initially with S-1 plus cisplatin. The optimal antiemetic therapy may differ in different types of cancer and in patients receiving different chemotherapeutic regimens. New strategies are needed to further improve nausea and loss of appetite in cancer patients receiving chemotherapy.

Acknowledgments We would like to thank all of the investigators who participated in this study. Study participants—Drs. Masato

Springer
Kiriya (Kurobe City Hospital, Toyama, Japan); Hiroshige Kimura (Keiyo Kanazawa Hospital, Ishikawa, Japan); Koji Nishijima (Red Cross Kanazawa Hospital, Ishikawa, Japan).

Compliance with ethical standards

Conflict of interest The authors declare that they have no conflict of interest.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

1. Bender CM, McDaniel RW, Murphy-Ende K et al (2002) Chemotherapy-induced nausea and vomiting. Clin J Oncol Nurs 6:94–102
2. de Boer-Dennert M, de Wit R, Schmitz PI et al (1997) Patient perceptions of the sideeffects of chemotherapy: the influence of 5HT3 antagonists. Br J Cancer 76:1055–1061
3. Hickok JT, Roscoe JA, Morrow GR et al (2003) Nausea and emesis remain significant problems of chemotherapy despite prophylaxis with 5-hydroxytryptamine-3 antagonists: a University of Rochester James P. Wilmot cancer center community clinical oncology program study of 360 cancer patients treated in the community. Cancer 97:2880–2886
4. Lindley CM, Hirsch JD, O’Neill CV et al (1992) Quality of life consequences of chemotherapy-induced emesis. Qual Life Res 1:331–340
5. Bloechl-Daum B, Deuson RR, Mavros P et al (2006) Delayed nausea and vomiting continue to reduce patients’ quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment. J Clin Oncol 24:4472–4478
6. Ihle-Heffinger A, Eihken B, Bernard R et al (2004) The impact of delayed chemotherapy-induced nausea and vomiting on patients, health resource utilization and costs in German cancer centers. Ann Oncol 15:526–536
7. Tavorath R, Hesketh PJ (1996) Drug treatment of chemotherapy-induced delayed emesis. Drugs 52:639–648
8. Aapro MS, Alberts DS (1981) High-dose dexamethasone for prevention of cisplatin-induced vomiting. Cancer Chemother Pharmacol 7:11–14
9. Gralla RJ, Osoba D, Kris MG et al (1999) Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. J Clin Oncol 17:2971–2994
10. Jantunen IT, Kataja VV, Muhonen TT (1997) An overview of randomised studies comparing 5-HT3 receptor antagonists to conventional anti-emetics in the prophylaxis of acute chemotherapy-induced vomiting. Eur J Cancer 33:66–74
11. Lattreille J, Pater J, Johnston D et al (1998) Use of dexamethasone and granisetron in the control of delayed emesis for patients who receive highly emetogenic chemotherapy. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 16:1174–1178
12. Tsukada H, Hirose T, Yokoyama A et al (2001) Randomized comparison of ondansetron plus dexamethasone with dexamethasone alone for the control of delayed cisplatin-induced emesis. Eur J Cancer 37:2398–2404
13. Koizumi W, Narahara H, Hara T et al (2008) S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 9:215–221
14. Oyama K, Fushida S, Kaji M et al (2013) Aprepitant plus granisetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients with gastric cancer treated with S-1 plus cisplatin. J Gastroenterol 48:1234–1241
15. Feyer P, Jordan K (2011) Update and new trends in antiemetic therapy; the continuing need for novel therapies. Ann Oncol 22:30–38
16. Gralla R, Lichinitser M, Van der Vegt S et al (2003) Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol 14:1570–1577
17. Eisenberg P, Figueroa-Vadillo J, Zamora R, 99–04 Palonosetron Study Group et al (2003) Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron. Cancer 98:2473–2482
18. Aapro M, Grunberg S, Manikhas G et al (2006) A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Ann Oncol 17:1441–1449
19. Saito M, Aogi K, Sekine I et al (2009) Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial. Lancet Oncol 10:115–124
20. Rojas C, Stathis M, Thomas AG et al (2008) Palonosetron exhibits unique molecular interactions with the 5-HT3 receptor. Anesth Analg 107:469–478
21. Rojas C, Thomas AG, Alt J et al (2010) Palonosetron triggers 5-HT(3) receptor internalization and causes prolonged inhibition of receptor function. Eur J Pharmacol 626:193–199
22. Rojas C, Slusher BS (2012) Pharmacological mechanisms of 5-HT3 and tachykinin NK1 receptor antagonism to prevent chemotherapy-induced nausea and vomiting. Eur J Pharmacol 684:1–7
23. Decker GM, DeMeyer ES, Kisko DL (2006) Measuring the maintenance of daily lives activities using the functional living index-emesis (FLIE) in patients receiving moderately emetogenic chemotherapy. J Support Oncol 4:35–41:52
24. Schwartzberg L, Barbour SY, Morrow GR et al (2014) Pooled analysis of phase III clinical studies of palonosetron versus ondansetron, dolasetron, and granisetron in the prevention of chemotherapy-induced nausea and vomiting (CINV). Support Care Cancer 22:469–477
25. Japan Society of Clinical Oncology (2010) Guidelines for antiemetics in oncology, 1st edn. Kanahara shuppann, Tokyo
26. Martin AR, Pearson JD, Cai B et al (2003) Assessing the impact of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. J Support Oncol 4(35–41):52
27. Satou A, Yamazaki T, Nukariya N et al (2002) Development of a Japanese version of the FLIE and validation of the community. Cancer 98:2473–2482
28. Popovic M, Warr DG, Deangelis C et al (2014) Efficacy and safety of palonosetron for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV): a systematic review and meta-analysis of randomized controlled trials. Support Care Cancer 22:1685–1697
29. Kitazaki TL, Fukuda Y, Fukahori S et al (2015) Usefulness of antiemetic therapy with aprepitant, palonosetron, and dexamethasone for lung cancer patients on cisplatin-based or carboplatin-based chemotherapy. Support Care Cancer 23:185–190

30. Takeshima N, Matoda M, Abe M et al (2014) Efficacy and safety of triple therapy with aprepitant, palonosetron, and dexamethasone for preventing nausea and vomiting induced by cisplatin-based chemotherapy for gynecological cancer: kCOG-G1003 phase II trial. Support Care Cancer 22:2891–2898

31. Tsukahara K, Nakamura K, Motohashi R et al (2014) Antiemetic therapy of fosaprepitant, palonosetron, and dexamethasone combined with cisplatin-based chemotherapy for head and neck carcinomas. Acta Otolaryngol 134:1198–1204

32. Hashimoto H, Yamanaka T, Shimada Y et al (2013) Palonosetron (PALO) versus granisetron (GRA) in the triplet regimen with dexamethasone (DEX) and aprepitant (APR) for preventing chemotherapy-induced nausea and vomiting (CINV) in patients (pts) receiving highly emetogenic chemotherapy (HEC) with cisplatin (CDDP): A randomized, double-blind, phase III trial. ASCO2013 Annual Meeting abstr #9621. http://meetinglibrary.asco.org/content/111042-132. Accessed 8 Aug 2013

33. Fujiwara S, Terai Y, Tsunetoh S et al (2015) Palonosetron versus granisetron in combination with aprepitant for the prevention of chemotherapy-induced nausea and vomiting in a population with gynecologic malignancy treated with moderately emetogenic chemotherapy. J Gynecol Oncol. [Epub ahead of print]